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HIGHLY POTENT CD22-RECOMBINANT RICIN A RESULTS IN COMPLETE 
CURE OF DISSEMINATED MALIGNANT B-CELL XENOGRAFTS IN SCID 
MICE BUT FAILS TO CURE SOLID XENOGRAFTS IN NUDE MICE
Peter J. Van H o r s s e n 1, Frank W.M.B. P r e ije r s , Ypke VJ.M . Van O o st e r h o u t  and Theo D e W itte 
Department of Hematology, University Hospital St. Radboud, Nijmegen, The Netherlands.
The highly specific cytotoxic action of ribosome-inactivating 
protein (RIP) containing immunotoxins (ITs) makes IT  therapy a 
promising approach to eliminating residual malignant cells. W e 
investigated the cytotoxicity of the IT CD22-recombinant ricin 
A to the B-cell line Ramos in vitro and in vivo. Cytotoxicity of 
CD22-recombinant ricin A in vitro was very high as expressed 
by the very low 50% inhibition dose (ID S0) of 3.5 X  10“ M M. 
Cytotoxicity was increased 7 times in the presence of the 
cytotoxicity enhancer N H 4CI. The ultimate kill of Ramos cells by 
CD22-recombinant ricin A was high (2.7-log kill) and was 
increased strongly in the presence of N H 4CI (4.2-log kill). 
Anti-tumor activity in vivo was investigated by i.v. treatm ent of 
solid s.c. Ramos xenografts in nude BALB/c mice. A  single dose 
did not inhibit tumor growth. Treatm ent on 5 consecutive days 
resulted in evident tumor reduction. In one mouse, tumor could 
no longer be detected on the 6th day after starting treatment. 
However, after 8 days tumor volumes increased again. Anti­
tumor activity was more pronounced in a disseminated tumor 
model in SCID mice. IT  treatm ent (i.v.) 7 days after i.v. 
inoculation with Ramos cells resulted in cure of all mice. 
Non-specific toxicity was low. Alanine aminotransferase (ALAT) 
levels in serum were elevated temporarily. Serum values of 
Y-glutamyl transferase (7-G T), bilirubin and creatinin did not 
change. Body weight was also transiently reduced. The LDS0 in 
SCID mice after i.v. administration was high (0.626 mg IT per 
mouse). The clearance rate in SCID mice, as determined by 
ELISA, was biphasic.
© 1996 Wiley-Liss, Inc.
Residual malignant ceils in autologous bone-marrow trans­
plants, as well as in patients who suffer from leukemia and 
lymphoma, are responsible for relapse after transplantation. 
The ability to kill malignant cells specifically renders therapy 
with ribosome-inactivating protein (RIP) containing ITs an 
excellent treatment to be applied in addition to chemotherapy, 
radiotherapy and/or surgery. ITs consist of a targeting com­
pound and a toxin (Preijers, 1993).
Ricin, a plant lectin, is the toxic agent most frequently used 
to construct ITs. Ricin occurs naturally as a heterodimer 
composed of the cytotoxic A chain that is linked by a 
disulphide bond to a galactose-residue-binding B chain (Lord 
et al, 1994). Substitution of the B chain by a specific targeting 
compound such as a monoclonal antibody (MAb) gives rise to 
specific cell kill by the ricin A chain. Disulphide-bridge- 
containing heterobifunctional linkers are often used to couple 
the MAb to the ricin A  chain. After binding and internaliza­
tion of the IT, the enzymatic ricin A chain is translocated to the 
cytosol. By cleaving the N-glycosidic bond of a single adenosine 
residue of 28S rRNA of the 60S ribosomal sub-unit (Endo and 
Tsurugi, 1988), ricin A catalytically and irreversibly inhibits 
protein synthesis of eukaryotic cells (Lord et al, 1994) and 
causes cell death.
The potency of ITs depends on several factors, such as the 
kind of antigen, the antigen density and number of internal­
ized IT molecules (Preijers et a l, 1988) and the intracellular 
routing and processing (Van Horssen et al, 1995). Additional 
factors influencing in vivo efficacy are the IT half-life, the 
dose-limiting non-specific toxicity, anti-IT reactions (Ghetie 
and Vitetta, 1994) and accessibility of the target cells. The 
large size of ITs may reduce the passage through the vascular
endothelium into the interstitial space of solid tumors (Ded- 
rick and Flessner, 1989).
IT treatment may be limited by non-specific toxicity of ricin
A, which in man appears to be vascular leak syndrome (VLS) 
(Ghetie and Vitetta, 1994). In mice, VLS does not occur, due 
to resistance of murine endothelial cells to ricin A (Soler- 
Rodríguez et al, 1993). Toxicity in mice is expressed by 
changes in hepatic and renal characteristics and loss of body 
weight. The LD5n for IgG-ricin A ITs varies between 0.30 and 0.72 
mg IT/25 g mouse (Ghetie et al, 1991,1992; Blakey etal., 1988).
In order to develop an effective treatment with IT of 
patients suffering from B-cell malignancies, a suitable tumor- 
model must be studied. CD22 MAbs bind to the B-lymphocyte 
adhesion molecule (Bl-CAM) expressed on the surface of B 
cells from the pro-B-cell stage to the mature B-cell stage 
(Kehrl et al, 1994). After binding, the Bl-CAM/IT complex is 
rapidly internalized and Bl-CAM is re-expressed (Van Hors­
sen et al, 1995; Shih et al, 1994), indicating its potential as 
target for IT therapy. Many investigators have shown, in vitro 
and in vivo, that CD22 ITs have strong anti-B-cell potency 
(Ghetie et al, 1988; Shen et al, 1988; Kreitman et al, 1993; 
Van Horssen et al, 1995). This potency has been shown in 
clinical phase I trials with CD22-deglycosyIated ricin A in over 
100 patients with B-cell lymphoma (Vitetta et al, 1991; Amlot 
etal, 1993; Sausvilleetal, 1995).
We investigated the efficacy of CD22 coupled to recombi­
nant ricin A to the Burkitt lymphoma cell line Ramos in vitro 
and in vivo. IT treatment of solid SC tumors in nude mice and 
of disseminated tumors in SCID mice was compared in 
different administration schedules, in order to study the 
influence of the accessibility of tumor cells. We treated the 
SCID mice after clear establishment of the tumor cells. The 
survival and pharmacokinetics and toxicity of CD22-recombi- 
nant ricin A were evaluated.
MATERIAL AND METHODS
Cell lines
The Burkitt-lymphoma cell line Ramos was cultured in 
medium consisting of RPMI 1640 (Flow, Irvine, UK) supple­
mented with 10% heat-inactivated FCS (Integro, Zaandam, 
The Netherlands), 2 mM glutamine, 50 U/ml penicillin and 50 
ptg/ni 1 streptomycin (Flow) in a humidified incubator with 5% 
C02 iti air at 37°C. Cells were maintained in log phase.
Animals
Seven- to eight-week-old nude BALB/c (BALB/c nu/nu) 
mice (male; University of Nijmegen, The Netherlands) and 
7- to 9-week-old SCID (C.B.-17/IcrBom-scid) mice (male; 
Bomholtgárd Breeding and Research Centre, Ry, Denmark) 
were used. Mice were housed in filtercap cages (micro­
isolators) placed in laminar airflow (LAF) cabinets. Mice were 
fed irradiated food and acidified drinking water. All manipula­
tions with the animals were performed in the LAF cabinets.
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Monoclonal antibody (MAb)
The murine MAb CD22 (CLB-B-ly/1; IgGi; CLB, Amster­
dam, The Netherlands) was produced in a hollow-fibre biore­
actor and was purified from the supernatant by affinity 
chromatography using staphylococcal protein A-Sepharose 
(Pharmacia, Uppsala, Sweden).
Immunotoxin preparation
CD22 was coupled to recombinant ricin A chain (generously 
provided by Zeneca, Macclesfield, UK) by means of 4-succin- 
imidyloxylcarbonyl-methyl-a-[2-pyridylditliio]toluene (SMPT; 
synthesized by the Department of Organic Chemistry, Univer­
sity of Nijmegen, The Netherlands) according to Thorpe et al
(1987). Briefly, 10 mg CD22 (in 1 ml 25 mM sodium borate, pH 
9) was treated with a 10-fold molar excess of SMPT (110 jxl of 1 
mg/ml SMPT solved in N,N-dimethylformamide; DMF, Merck, 
Darmstadt, Germany) with gentle rotation during 1 hr at 20°C. 
Free SMPT and DMF were removed by gel filtration on a 
Sephadex G25 (Pharmacia, Uppsala, Sweden) column. To 
introduce a free sulfhydryl group, ricin A was incubated in 50 
mM DTT for 30 min at 20°C. DTT was removed by gel 
filtration on the G25 column. The modified MAb was incu­
bated with a 2.5 molar excess ricin A for 72 hr at 20°C, resulting 
in a coupling ratio (ricin A:MAb) of 1.1. Free ricin A was 
separated from the IT by gel filtration on a Sephacryl S200 
High Resolution (Pharmacia) column.
Protein-synthesis-inhibiting activity of CD22-recombinant ricin A
Cells (105) in culture medium were incubated with various 
concentrations of CD22-recombinant ricin A (10” 13 to 10“B M) 
in the presence or absence of 6 mM NH4C1 in a final volume of 
200 jjlL Incubation was performed in 96-well microtiter plates 
(Costar, Cambridge, MA) in triplicate for 24 hr at 37°C. 
Subsequently, 0.5 |xCi [3H]leucine (Amersham, Aylesbury, 
UK) was added. After 24 hr, cells were harvested and the 
radioactivity was measured. Cytotoxicity was expressed as the 
percentage of [3H]leucine incorporation with regard to un­
treated cells corrected for non-specific incorporation deter­
mined by incubating cells in the presence of 1 mM cyclohexi- 
mide (Boehringer, Mannheim, Germany).
Cell kill by CD22-recombinant ricin A
Cell kill was determined according to a method described by 
Van Oosterhout et al. (1994). Briefly, cells were incubated with 
or without 10“8 M CD22-recombinant ricin A in the presence 
and absence of 6 mM NH4C1 for 24 hr. Thereafter, cells were 
washed and incubated in fresh culture medium for 3 days. 
Then, 45 min before flow-cytometric analysis (Epics Elite, 
Coulter, Hialeah, FL) propidium iodide (PI; 20 jxg/ml) was 
added to stain dead cells, and calcein (20 (Jig/ml) was added to 
stain living cells. Inert beads (5 x 104/ml, DNA-Check, 
Coulter) were added to permit quantification of cell kill. In the 
samples, the number of living cells was quantified by simulta­
neously measuring an appropriate number of beads. The 
number of living cells per 1000 beads of a treated sample was 
compared with the number of living cells per 1000 beads in the 
control sample, to calculate the factor of depletion.
Pharmacokinetics of CD22-recombinant ricin A following 
L v. administration
IT (60 |xg) in 0.1 ml PBS was injected into the tail vein of 
SCID mice. After 5,10,15 and 30 min, and 1,2, 4, 8,16,24, 48 
and 72 hr, blood samples were taken by orbital puncture. After 
clotting for one hour, serum was separated and stored at 
—20°C. Serum concentrations of CD22-recombinant ricin A 
were determined in an enzyme-linked immunosorbant assay
(ELISA).
ELISA for determination of serum levels of 
CD22-recombinant ricin A
An ELISA slightly different from that described by Calvete 
et al (1993) was used to quantify CD 22-recombinant ricin A 
concentrations in serum. Briefly, 96-well flat-bottomed plates 
(Costar) were coated (16 hr at 4°C) with 100 jxl rabbit 
anti-ricinus communis lectin (Sigma, Poole, UK) diluted 1:500 
in PBS. Thereafter the plates were blocked with PBS contain­
ing 1% (w/v) gelatin (blocking buffer). After 30 min incubation 
at room temperature, plates were washed 5 times with PBS 
containing 0.05% (w/v) Tween-80. Plates were incubated for 1 
hr with 100 [xl serum samples (pre-diluted 20 times in PBS) 
diluted 1:2 step wise in blocking buffer. Each plate contained 
7 samples and one control sample, starting at 0.9 ^g/ml 
(4 x 10"9 M). After washing 5 times, 100 jxl of horseradish- 
peroxidase-labelled goat-anti-mouse IgGi (Southern Biotech­
nology Associates, Birmingham, AL), 1:500 diluted in blocking 
buffer, was added for another hour. After washing, the colour 
reaction was performed with the tetramethyl-benzidine (TMB) 
Microwell Peroxidase Substrate System (Kirkegaard and Perry, 
Gaithersburg, MD) and stopped after 5 min with 100 \jA IN 
H3NO2; the A450 nm was then determined (EAR 400 Easy 
reader Titertek, SLT, Groedig/Saizburg, Austria).
Establishment of the Ramos xenograft tumor model 
in nude mice and IT therapy
Ramos cells were washed and re-suspended at 108 cells/ml 
in PBS. Cells were injected (0.1 ml) s.c. and the mice were 
monitored daily for developing tumors. Tumor volume was 
measured by sliding callipers (volume = Vi x length x 
width x height) (Tomayko and Reynolds, 1989). Treat­
ment was started when tumor volume was 100 mm3. Mice were 
treated i.v. with 30 fxg IT once or 5 times on consecutive days. 
Control mice were injected with PBS or 25 ^g IT. Each group 
consisted of 5 mice. Statistical significance was evaluated by 
Student’s /-test.
Establishment of the Ramos xenoginft tumor model 
in SCID mice and IT therapy
Ramos cells were prepared as described for nude mice. Mice 
were inoculated i.v. with 1G7 cells 7 days before treatment. The 
control mice (10 mice) were injected with PBS. Mice were 
treated i.v. with 30 or 60 IT once or 5 times with 30 or 60 jxg 
IT on consecutive days (5 mice per group). One group was 
treated with 250 [xg CD22 MAb. Mice were observed daily for 
the onset of posterior paralysis and killed at occurrence. The 
mean paralysis time (MPT) was used to express efficacy of 
treatment. Statistical significance was evaluated by the 2-tailed 
log-rank test.
Toxicity of IT therapy
SCID mice administered once or 5 times with 30 or 60 jxg (3 
mice per group) were observed for IT toxicity. At days 3, 7, 12 
and 21 after starting treatment, 200 jjlI blood was collected by 
orbital puncture. After clotting for L5 hr, serum was isolated 
and renal and hepatic enzymes were determined with the 
Hitachi 747 (Boehringer). Creatinin levels were determined to 
examine renal activity and bilirubin, ALAT and 7-GT for 
hepatic damage. Body weight of all mice was determined at 
least 3 times a week at the beginning of the experiment, once a 
week at the end of the experiment.
De term in a tion of LD5q
SCID mice were injected i.v. with 0.47, 0.60, 0.77 and 1.0 mg 
IT and observed for death. The LD50 was calculated according 
to Weil (1952).
RESULTS
Cytotoxicity of CD22-re comb inant ricin A
Treatment of Ramos cells with CD22-recombinant ricin A 
resulted in strong inhibition of protein synthesis. Cytotoxicity,
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F ig u r e  1 -  Cytotoxicity of CD22-recombinant ricin A to Ramos 
determined in a protein-synthesis-inhibition assay in the absence 
( • )  and in the presence (O) of 6 mM NH4CL Assays were 
performed in triplicate. SD < 10%.
expressed by ID 50, was 3.5 x 10“ 11 M (Fig. 1). In the presence 
of 6 mM of the enhancer NH4CI, which enhances the activity of 
ricin A  ITs in ex vivo treatment of bone marrow, the ID5t} was 
5.0 x 10" 12 M (Fig. 1). IT concentrations of 10" 9 M or higher 
resulted in complete inhibition both in the absence and 
in the presence of NH4C1.
Although inhibition of protein synthesis is informative 
regarding IT activity, it does not reflect the ultimate cell kill. 
Therefore we determined elimination of cells by IT in a 
quantitative flow cytometric assay. Cells were incubated during 
24 hr with 10' 8 M IT. After a retention period of 3 days, 
samples were analyzed. The number of eliminated target cells 
was determined by comparing the number of living cells 
(calcein-positive and Pi-negative) in the treated sample and 
the control sample for each 1000 beads added to the samples. 
Beads were detected separately from the cells by flow cytome­
try. Treatment of Ramos cells with CD22-recombinant ricin A 
resulted in a 2.7-log kill in the absence and a 4.2-log kill in the 
presence of NH 4CI (Table I).
►
Establishment and treatment of an sx. Ramos xenograft 
in nude BALB/c mice
To determine the anti-tumor activity of CD22-recombinant 
ricin A in vivo, 107 Ramos cells were injected s.c. in nude 
BALB/c mice. The time period to detect tumor growth varied 
among mice. Tumors developed only in 64% of the mice. 
Treatment with CD22-recombinant ricin A  was started when 
tumor volume was approximately 100 mm3. In the first experi­
ment, mice were treated i.v. with 30 [Lg IT, 25 fxg CD22 MAb 
or PBS as control (Fig. 2a). Increase of the mean tumor 
volume proved that a single administration of 30 |xg IT or 25 jxg 
CD22 MAb had no significant effect on tumor growth. From 
each group, one Ramos xenograft was isolated and cells were 
assessed for CD22 antigen expression and susceptibility to 
CD22-recombinant ricin A IT. Cells isolated from treated and 
untreated xenografts expressed comparable CD22 antigen but 
lower amounts, as compared with cells in a parallel in vitro 
culture. However, cytotoxicity of CD22-recombinant ricin A to 
the xenograft-derived Ramos cells was higher than to the cells
-NH<CI + 6 mM NH4CI
Control sample 295357 215611
Treated sample 603 14
Log kill 2.7 4.2
Cytotoxicity of CD22-recombinant ricin A to Ramos deter­
mined by flow cytometric analysis. Cells were incubated for 24 hr 
in the absence or the presence of 10' s M CD22-recombinant ricin 
A. After a lag period of 3 days} calcein and propidium iodide were 
added to detect living cells (calcein-positive and propidium-iodide- 
negative) and inert beads to enable the quantification of cell kill. 
See “Material and Methods”. Assays were performed 3 times. SD 
in log kill was less than 10%.
in culture, resulting in an approximately one log lower ID50 
(data not shown).
In a second experiment, mice were treated on 5 consecutive 
days with PBS or 30 |xg IT (total dose 150 |xg). Anti-tumor 
activity was more pronounced. From day 3, tumor growth was 
significantly reduced (p < 0.05). Not only was tumor growth 
inhibited but even tumor size was temporarily reduced (Fig. 
2b). Out of 5 mice, 1 had no detectable tumor during the first 2 
days after IT treatment. Tumors started to grow again on the 
third or fourth day after treatment.
Establishment and treatment of an i.v. Ramos xenograft 
in SCID mice
In order to study in vivo treatment of a hematological tumor 
that is more comparable with a disseminated tumor in patients, 
we developed a model in SCID mice, Mice were inoculated i.v. 
with 107 Ramos cells. Initially, we tested variation in tumor 
growth resulting in paralysis of the hind legs in all mice. 
Paralysis occurred in one mouse 22 days after and in the other 
5 mice 23 days after inoculation of the Ramos cells. To 
determine the anti-tumor effect of CD22-recombinant ricin A, 
mice were treated i.v. 7 days after inoculation. They received 
PBS, 250 fxg CD22 MAb, 30 or 60 \xg IT once or 5 times 30 or 
60 jxg IT on consecutive days. The mean paralysis time (MPT) 
of the control group was 30.1 ± 2.5 days whereas the MPT of the 
group treated with the MAb was significantly increased (p = 0.045) 
to 36.4 ±1.1 days (Fig. 3). Even with the lowest IT dose, treatment 
of the mice resulted in cure of all mice. The experiment was ended 
175 days after the inoculation with Ramos cells.
Toxicity of CD22-recombinant ricin A
Non-specific toxicity of IT therapy was investigated in SCID 
mice. After injection of 30, 60 or 5 x 30 or 60 [ig IT liver and 
renal enzymes in serum and total body weight were deter­
mined in follow-up. Creatinin, bilirubin and y-GT levels did 
not change but ALAT levels were temporarily elevated and 
normalized within 3.5 weeks (data not shown). Body weight 
decreased depending on the dose used. It was reduced 18% in 
the highest dose group (5 x 60 |xg), 9% in the group adminis­
tered with 5 x 30 |xg and 5% or less in the groups tested with 
lower doses. The reduction lasted 9 weeks in the group 
injected with the highest dose (5 X 60 p.g) to 3 days in the 
group injected with the lowest dose (30 jxg IT) (Fig. 4).
Pharmacokinetics of CD22-recombinant ricin A in SCID mice
To determine the blood clearance rate of CD22-recombi- 
nant ricin A, SCID mice were injected i.v. with 60 |xg IT. After 
vaiying periods of time, blood was isolated and the IT 
concentration was determined in serum by ELISA, as de­
scribed in “Material and Methods'*. The decrease of IT in 
serum could be distinguished in 2 phases (Fig. 5). The 
clearance of IT was fast during the first 16 hr (T!/2a is 12.1 hr) 
and slowed down thereafter (T‘/2p is 53.6 hr). After injection of
60 [jjg IT, the IT concentration in serum after 72 hr was still 
more than 10"8 M (Fig. 5).
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F igure  2 - Treatment of a SC Ramos xenograft in nude mice. 
Ramos cells (107) were injected s.c. and mice were treated when 
the tumor volume was approximately 100 mm3. Mice were treated 
with PBS (•) , 25 jxg CD22 (■) or 30 p,g CD22-recombinant ricin 
A (O) (a) and with PBS ( • )  or 5 x 30 CD22-recombinant ricin 
A (O) (b). All groups consisted of 5 mice. Tumor volume was 
determined daily. Difference between the control and the IT- 
treated group was significant (p < 0.05), starting on day 3.
LD5o of CD22-recombinant ricin A in SCID mice
The median lethal dose was determined in mice that were 
injected i.v. with varying doses IT. The LD50 was calculated 
according to the method of Weil and appeared to be 0.626 mg 
IT (0.104 mg ricin A) per mouse (25 g). Occasionally, the LD50 
of IT in mice is determined after i.p. injection. Therefore 
experiments were repeated with i.p. injection of the IT. These 
mice survived the 2 highest doses that were injected i.v. (0.77 
and 1.0 mg), and that killed them all. This indicates that the 
LD50 of i.p.-injected IT is more than 1.0 mg.
DISCUSSION
In this study we showed the high cytotoxic potency of 
CD22-recombinant ricin A to the B-cell line Ramos, with ID50 
values of 3.5 x 10“ 11 M in the absence and 5.0 X 10~I2Minthe
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F igure  3-Treatment of a disseminated Ramos xenograft in 
SCID mice. Ramos cells (107) were injected i.v. 7 days prior to i.v. 
treatment with PBS ( • ) , 250 jjug CD22 (□) or once or 5 times with 
30 or 60 jxg IT (■). All groups consisted of 5 mice, except the 
PBS-treated group (10 mice). Mice were monitored daily for 
occurence of paralysis. The experiment represents one of 3 
reproducible experiments.
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F igure  4 - Influence of IT treatment on the body weight of 
SCID mice. Body weight of mice was determined almost daily after 
administration of 30 (■), 5 x 30 (□), 60 ( • )  or 5 x 60 (O) jxg 
CD22-recombinant ricin A.
presence of 6 mM NH4CI. Previously we have shown that CD22- 
recombinant ricin A was fast-acting and that the cytotoxic potency 
of CD22-recombinant ricin A depends on intracellular processing 
rather than on antigen density and the number of internalized 
molecules (Van Horssen et at., 1995). Therefore CD22-recombi- 
nant ricin A is highly cytotoxic even to cells that express low 
numbers of antigens (Van Horssen et al, 1995).
ID 50 values do not predict the elimination of target cells. 
Therefore we determined the effective cell kill induced by IT 
treatment in a quantitative flow cytometric assay. Treatment of 
Ramos cells with 10“ 8 M CD22-recombinant ricin A resulted 
in a 2.7-log elimination in the absence and a 4.2-log elimina­
tion in the presence of NH4C1. This means that only 1 out of 
every 15,400 cells survived. These results showed that the
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Figure 5 - Blood clearance of CD22-recombinant ricin A in 
SCID mice. Mice were injected i.v. with 60 p,g CD22-recombinant 
ricin A (each group, n = 5). Blood was obtained after varying time 
periods and the concentration CD22-recombinant ricin A was 
determined in serum by ELISA, as described in “Material and 
Methods”. The pharmacokinetics of CD22-recombinant ricin A is 
biphasic, with a TVact of 12.1 hours and a Tl/>fS of 53.6 hr.
strong protein-synthesis inhibition of CD22-recombinant ricin 
A results in effective cell elimination.
Many investigators have shown that CD22 ITs have strong 
anti-B-cell potency (Ghetie et al, 1988; Shen et al, 1988; 
Kreitman et al, 1993; Van Horssen et al, 1995). In mice, i.p. 
treatment with CD22 IT prevented or caused complete regres­
sion of measurable SC tumors, but failed to induce cure 
(Kreitman et al, 1993). CD22-deglycosylated ricin A treatment
i.v. 24 hr after i.v. inoculation of tumor cells resulted in a more 
pronounced anti-tumor effect. Time before onset of paralysis 
was significantly postponed, but mice were not cured (Ghetie 
et al, 1991, 1992, 1994). These results gave rise to phase I 
studies in man, in which partial responses and one complete 
response were obtained (Vitetta et al, 1991; Amlot et a l, 
1993). In another phase I study, continuous infusion of 
CD22-deglycosylated ricin A resulted in 4 partial and 3 minor 
responses (Sausville et al, 1995).
To compare the in vivo efficacy of CD22-recombinant ricin A 
with compact growing and disseminated malignant B-cells, we 
used 2 xenograft mouse models. In a nude-mice model, Ramos 
cells were injected s.c., resulting in a solid tumor. Tumor take 
was successful in only 64% of the animals, and the onset of 
detection varied extensively. This may have been due to the 
remaining immunologic system in the nude mice. After estab­
lishment of the tumor, the growth rate was comparable 
between individual mice, indicating that the immunologic 
system was completely suppressed in the tumor-bearing mice. 
Treatment with IT resulted in 4 partial responses and one 
complete response when the mice were treated 5 times with 30 
p-g IT on consecutive days. However, tumor volumes increased 
3 days after the last IT administration.
The potency of CD22-recombinant ricin A to eliminate 
disseminated malignant B-cells was studied in a SCID-mice 
model. This model mimics well B-cell leukemias in humans. 
Mice injected i.v. with Ramos developed disseminated disease, 
resulting in paralysis of the hind legs (Ghetie et al, 1990).
Tumor take was 100% in this model, with a small variation in 
paralysis time. MAb treatment postponed the MPT, and IT 
treatment with doses as low as 30 p,g cured all mice.
The better results of CD22-recombinant ricin A treatment 
of disseminated tumors as compared with those for treatment 
of solid tumors may be explained by differences in the number 
of tumor cells at the moment of starting treatment or in 
accessibility of the cells. The large size of ITs constructed with 
intact MAbs may result in reduced penetration in a solid tumor 
(Dedrick and Flessner, 1989). Smaller CD22 IT, containing 
antibody fragments coupled to a truncated form of Pseudomo- 
nas exotoxin, have been shown to be more effective in 
eradicating solid tumors in spite of the lower affinity due to the 
monovalent binding (Kreitman et al, 1993). The higher affinity 
of intact MAb ITs may make them superior for elimination of 
easily accessible target cells (Ghetie et a l, 1991). In contrast, 
fragmented ITs have higher tumor-penetration capacity, result­
ing in greater elimination of solid tumors (Kreitman et al, 
1993). In the SCID model, target cells home mainly on to 
blood, bone marrow and lymphoid tissues. The IT, which is 
also administered i.v., may more easily reach those cells than 
cells in a poorly vascularized solid tumor.
The blood clearance of CD22-recombinant ricin A was 
determined in SCID mice. The pharmacokinetics were bipha­
sic, with a Ty2ct of 12.1 and a TVip of 53.6 hr. These half-life 
times were much longer than IT half-life times in mice found 
by other investigators (Fulton et al, 1988). The Tl/2a of these 
ITs ranged from 11 to 51 minutes and the T!/2p varied from 4 to 
22 hours (Fulton et al, 1988). The differences in T'/ia may be 
explained by the type of ricin A chain that was used. We used 
aglycosyl recombinant ricin A, while Fulton et al (1988) used 
native or deglycosylated ricin A. As a consequence, our IT 
would be less rapidly cleared by the liver, due to the differ­
ences in glycosylation of the ricin A moiety. The stability of the 
IT affects the T^p. We used the heterobifunctional linker SMPT, 
which contains a hindered disulphide bond, while Fulton et al
(1988) used SPDP, which lacks this hindrance. The enhanced in 
vivo stability of ITs produced with SMPT was showed by Thorpe et 
al (1987). Long half-lives (Tl/2a 2.8 and T/2p 33 hr) were also found 
for the IT ICI-D0490 constructed with the same recombinant ricin 
A and the methyl-hindered linker N-succinimidyl 3-(2-pyri- 
dyldithio)-3-methylproprionate) (Cálvetela/., 1993).
Treatment appeared to be hardly toxic, even with the 
highest dose (5 x 60 (jLg), suggesting that high doses of 
CD22-recombinant ricin A can be administered. This may 
improve the outcome of therapy. The long half-life may be an 
explanation for the low toxicity, due to lower accumulation of 
IT in the liver, which in mice is a target for IT toxicity. In man, 
however, prolonged contact of endothelial cells with ricin A 
will increase the chance of VLS. The LD50 is comparable or 
even higher than the LD50 found by other investigators (Ghetie 
et al, 1991,1992; Blakey etal, 1988). However, we determined 
the LD50 after i.v. administration of IT, whereas the other LD5o 
values were determined after i.p. injection. When our IT was 
injected i.p., even the highest dose (1 mg) did not result in the 
death of mice, indicating that recombinant ricin A IT is much less 
toxic than ITs prepared with native or deglycosylated ricin A.
We conclude that the CD22-recombinant ricin A IT used in 
our study is highly cytotoxic in vitro and in vivo in a model of 
disseminated growing tumor cells. However, cells in solid 
tumors are less well eliminated, which may be due to the lower 
penetrating capacity of intact MAb IT. The clearance of the IT 
from the blood and the non-specific toxicity are low. Therefore 
we propose that the CD22-recombinant ricin A IT used in our 
study is promising for in vivo treatment of patients suffering 
from B-cell leukemias and lymphomas. Efficacy of treatment
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might be improved by a combination with fragmented CD22 IT 
that has higher tumor-penetrating capacity.
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